β¨ Health and Education Notices
1684
NEW ZEALAND GAZETTE
No. 71
for such capital works associated with, the buildings and
associated facilities of the above-mentioned integrated
schools as may be required or approved by the Minister of
Education, pursuant to section 40 (2) of the Private
Schools Conditional Integration Act 1975, or for meeting
debts, mortgages, liens, or other charges associated with
any of the land and buildings that constitute the integrated
schools.
Dated at Wellington this 5th day of July 2001.
KATHY PHILLIPS, Senior Manager, National Operations.
go4737
Health
Medical Practitioners Act 1995
Appointment to the Medical Council of New Zealand
Pursuant to 124 (b) of the Medical Practitioners Act 1995,
I appoint
Professor A. John Campbell
as a member of the Medical Council of New Zealand for a
term of office commencing on the date of notification in the
New Zealand Gazette and expiring on 30 June 2002.
Dated at Wellington this 3rd day of July 2001.
ANNETTE KING, Minister of Health.
go4788
Medicines Act 1981
Consent to the Distribution of New Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of
the new medicine set out in the Schedule hereto:
Schedule
Product: Angiomax
Active Ingredient(s): Bivalirudin 100mg
Dosage Form: Powder for injection
New Zealand Sponsor: The Medicines Company
Manufacturer(s): Ben Venue Laboratories Inc, Bedford, Ohio, United States of America
Product: Angiomax
Active Ingredient(s): Bivalirudin 250mg
Dosage Form: Powder for injection
New Zealand Sponsor: The Medicines Company
Manufacturer(s): Ben Venue Laboratories Inc, Bedford, Ohio, United States of America
Product: Zyprexa Zydis
Active Ingredient(s): Olanzapine 10mg
Dosage Form: Wafer
New Zealand Sponsor: Eli Lilly and Company (NZ) Limited
Manufacturer(s): Scherer DDS Ltd, Blagrove, Swindon, Wiltshire, England
Product: Zyprexa Zydis
Active Ingredient(s): Olanzapine 15mg
Dosage Form: Wafer
New Zealand Sponsor: Eli Lilly and Company (NZ) Limited
Manufacturer(s): Scherer DDS Ltd, Blagrove, Swindon, Wiltshire, England
Product: Zyprexa Zydis
Active Ingredient(s): Olanzapine 20mg
Dosage Form: Wafer
New Zealand Sponsor: Eli Lilly and Company (NZ) Limited
Manufacturer(s): Scherer DDS Ltd, Blagrove, Swindon, Wiltshire, England
Product: Zyprexa Zydis
Active Ingredient(s): Olanzapine 5mg
Dosage Form: Wafer
New Zealand Sponsor: Eli Lilly and Company (NZ) Limited
Manufacturer(s): Scherer DDS Ltd, Blagrove, Swindon, Wiltshire, England
Dated this 4th day of July 2001.
G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of
February 1997).
go4702
Next Page →
Online Sources for this page:
VUW Te Waharoa —
NZ Gazette 2001, No 71
Gazette.govt.nz —
NZ Gazette 2001, No 71
β¨ LLM interpretation of page content
π Approval of Attendance Dues for Catholic Schools
π Education, Culture & Science5 July 2001
Attendance Dues, Catholic Schools, Integrated Schools, Private Schools Conditional Integration Act
- KATHY PHILLIPS, Senior Manager, National Operations
π₯ Appointment to the Medical Council of New Zealand
π₯ Health & Social Welfare3 July 2001
Medical Council, Appointment, Professor, Medical Practitioners Act
- A. John Campbell (Professor), Appointed to Medical Council of New Zealand
- ANNETTE KING, Minister of Health
π₯ Consent to the Distribution of New Medicines
π₯ Health & Social Welfare4 July 2001
Medicines, Distribution, Angiomax, Zyprexa Zydis, Bivalirudin, Olanzapine
- G. R. BOYD, Chief Advisor, Safety and Regulation